Form 4: Revvity CEO Singh Reports Planned Stock Sales, Option Exercises

Revvity CEO Prahlad R. Singh disclosed a series of planned stock transactions, including sales under a 10b5-1 plan, vesting of restricted stock units, and option exercises.

Summary

• Prahlad R. Singh, President, CEO, and Director of Revvity, Inc. (RVTY), reported multiple transactions involving common stock and derivative securities.
• On February 4, 2026, 3,421 shares of common stock were surrendered at $101.13 to satisfy tax withholding obligations upon the vesting of restricted stock units originally granted on February 4, 2025.
• Also on February 4, 2026, Singh acquired 26,796 time-based restricted stock units (RSUs) at a price of $0, which are scheduled to vest in three equal annual installments starting on the first anniversary of the grant date.
• On February 4, 2026, Singh was granted 76,647 Non-Qualified Stock Options with an exercise price of $103.395, vesting in three equal annual installments beginning on the first anniversary of the grant date (February 4, 2026) and expiring on February 4, 2033.
• On February 5, 2026, Singh exercised 25,525 Non-Qualified Stock Options at an exercise price of $92.09, which had become exercisable in three equal annual installments starting February 5, 2020.
• Following the option exercise, Singh sold a total of 25,525 shares of common stock on February 5, 2026, through multiple transactions at weighted average prices ranging from $99.02 to $102.52. These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2025.
• Singh's direct beneficial ownership of common stock after these transactions is 120,213 shares, with an additional 46,583 shares held indirectly by the Singh Family Trust of 2021.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. While there is insider selling, it is mitigated by the use of a 10b5-1 plan, indicating planned diversification rather than a lack of confidence. The grants of new RSUs and options are positive, aligning executive incentives with future company performance.

Positives

• Grant of 26,796 new restricted stock units (RSUs) at $0, aligning management's interests with long-term shareholder value.
• Grant of 76,647 new Non-Qualified Stock Options at an exercise price of $103.395, providing future incentive.
• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and systematic approach to managing personal holdings rather than a reaction to new, negative information.

Negatives

• Significant insider selling of 25,525 shares of common stock, even if planned, can sometimes be perceived as a lack of confidence, though this is mitigated by the 10b5-1 plan.
• The surrender of 3,421 shares for tax withholding reduces direct beneficial ownership.

Future Outlook

The filing indicates future vesting events for newly granted restricted stock units and stock options, which are scheduled to occur in three equal annual installments starting on the first anniversary of their respective grant dates (February 4, 2026, for both).

Management Comments

• The vesting schedule for the restricted stock unit grant to the Reporting Person included in the Form 4 filed on February 6, 2025 was incorrectly reported due to administrative error. The restricted stock unit grant included in that Form 4 is scheduled to vest in three equal annual installments beginning on the first anniversary of the date of grant.
• These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 4, 2025, as required by the Reporting Person's Restricted Stock Unit Agreement.
• Shares are time-based restricted stock units that are scheduled to vest in three equal annual installments beginning on the first anniversary of the date of grant.
• The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 6, 2025.
• The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
• Securities held in an irrevocable trust for the sole benefit of the Reporting Person's children. The Reporting Person's spouse is the trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• This option is scheduled to vest in three equal annual installments beginning on the first anniversary of the date of grant.
• This option became exercisable in three equal annual installments beginning on February 5, 2020, which was the first anniversary of the date on which the option was granted.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving executive officers like a CEO, are closely watched by the market. The use of a Rule 10b5-1 trading plan, as seen here, is a common practice among executives to sell shares systematically over time, mitigating concerns about sales being based on undisclosed material non-public information. This aligns with best practices for corporate governance in the industry, providing transparency and reducing the perception of opportunistic trading.

Comparison to Industry Standards

• The adoption of a Rule 10b5-1 trading plan by Revvity's CEO aligns with common corporate governance practices among S&P 500 companies, where such plans are widely used to manage executive stock sales in a pre-scheduled, compliant manner. For example, executives at companies like Pfizer or Thermo Fisher Scientific frequently utilize 10b5-1 plans for diversification and liquidity.
• The grant of restricted stock units and stock options as part of executive compensation is a standard practice across the biotechnology and life sciences tools industry, comparable to compensation structures at peers such as Danaher Corporation or Agilent Technologies, aiming to incentivize long-term performance and align executive interests with shareholder returns.
• The surrender of shares for tax withholding upon RSU vesting is a routine and expected event for equity compensation, consistent with practices observed at virtually all publicly traded companies offering such awards.

Corporate Governance

Related Party Transactions

• 46,583 shares of common stock are held indirectly by the Singh Family Trust of 2021, an irrevocable trust for the sole benefit of the Reporting Person's children, with the Reporting Person's spouse as trustee. The Reporting Person disclaims beneficial ownership except for any pecuniary interest.

Stakeholder Impact

• Shareholders: The planned sales under a 10b5-1 plan provide transparency regarding executive stock transactions. New equity grants align executive incentives with long-term shareholder value.
• Employees: The equity compensation structure, including RSUs and stock options, is a common incentive mechanism that can motivate performance.

Next Steps

• Future vesting of 26,796 restricted stock units in three equal annual installments beginning on February 4, 2027.
• Future vesting of 76,647 NQ Stock Options in three equal annual installments beginning on February 4, 2027.

Key Dates

Recommendation

This Form 4 primarily details routine, pre-planned insider transactions related to executive compensation and personal financial management. While there are sales, they are under a 10b5-1 plan, which typically reduces their negative signaling effect. The grants of new equity awards are a positive for long-term alignment. However, a Form 4 alone does not provide sufficient fundamental or strategic information to warrant a 'buy' or 'sell' recommendation; it primarily reflects an executive's personal financial planning. Therefore, a 'hold' is appropriate as it doesn't present new information that would fundamentally alter an investment thesis.

Keywords

Revvity, RVTY, Prahlad R. Singh, insider trading, Form 4, stock options, restricted stock units, 10b5-1 plan, executive compensation, share sales, beneficial ownership